Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

Next Previous
X
Search
Trial Profile

Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyrrolate (Primary) ; Neostigmine (Primary) ; Sugammadex (Primary) ; Remifentanil; Rocuronium bromide; Sevoflurane
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified April 2019 by Pavithra Ranganathan, West Virginia University.).
    • 26 Apr 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2020.
    • 26 Apr 2019 Planned primary completion date changed from 15 Dec 2018 to 15 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top